With one of its funds’ mandate to support companies eyeing an SGX listing, encouraging the medical group’s delisting through the other is a bad look
TALKMED Group late last year received a privatisation proposal from oncology-focused group Tamarind Health. But there was a curious player tagging along in the deal – Singapore-based global investment firm 65 Equity Partners.
As part of the privatisation deal, the Temasek-backed investment company will subscribe for shares in Tamarind Health through its local enterprise fund, gaining 18.3 per cent of the voting interest in Tamarind Health.
The participation of 65 Equity Partners in this deal is baffling.
Copyright SPH Media. All rights reserved.
